VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of -5.88% and -59.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?